Innovassynth Technologies (india) Ltd · BSE:INOVSYNTH
Innovassynth Technologies (india) — Q3 FY26 Earnings Presentation
9 slides from Innovassynth Technologies (india)'s earnings presentation, Feb 10, 2026
Slide 1: BSE filing cover letter for investor presentation
Date: 10th February 2026 To, Manager, Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code: 533315 Dear Sir/Madam, Sub: Investor Presentation for the quarter and nine months ended December 31, 2025 With reference to the subject, please find
Slide 2: Investor Presentation Q3FY26
Investor Presentation Q3FY26 10-February-2026
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Innovassynth Technologies India Limited (formerly known as Innovassynth Investments Limited). The presentation aims to cover key financial and business highlights. The words “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “proje
Slide 4: Business Model
Business Model Innovassynth has 3 business units Contract Research Life Sciences & Nucleosides Specialty Chemicals Development and Manufacturing Exports Led Business : ~90% of revenue from global geographies with key focus on US & EU. Our Life Sciences & Specialty Chemicals segments focus on develop
Slide 5: Innovassynth: At a Glance
Innovassynth: At a Glance Infrastructure People Service Capability 60+ 300+ Custom Research, Development & Acres of world class Total strength Manufacturing infrastructure including (CRDMO), HQ and R&D mfg. plant in Khopoli, in Pune, India near Mumbai area Quality Standards Manufacturing Capability
Slide 6: Financial Highlights
Financial Highlights Revenue EBIDTA PAT INR 22 Cr INR (4.5) Cr INR (7.5) Cr Q3 FY26 YTD INR 52 Cr YTD INR (31) Cr YTD INR (40.6) Cr • Company has a pipeline of products at various stages of commercialization. This augurs well for the long-term business prospects Revenue Split Across Regions • For al
Slide 7: Order Book Position
Order Book Position Company has a strong order book and has recently secured several promising new orders from U.S.- based Companies Life Sciences Specialty Chemicals CRDMO TOTAL INR 65 Cr INR 8 Cr INR 73 Cr INR ~146 Cr 6
Slide 8: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement Particulars Quarter Ended Year Ended Amount in 31-Dec-2025 30-Sep-2025 31-Dec-2024 31-Mar-2025 INR Lakhs Revenue from operations 2,197 1,728 4,991 9,831 Other Income 11 30 120 178 Total Income 2,208 1,758 5,111 10,009 Material Cost 354 739 1,649 3,583 Employee
Slide 9: Thank You
INN~ VASSYNTH Thank You Lm
Innovassynth Technologies (India) — Q3 FY26 Earnings Presentation on 6ix